reported fourth-quarter adjusted earnings that beat Wall Street estimates but sales fell 12% from a year earlier on what the company called an “expected year-over-year decline in Covid-19 testing-related sales.”
Abbott (ticker: ABT) shares were down 1.8% in premarket trading.
Abbott reported an adjusted fourth-quarter profit of $1.03 a share, beating forecasts of 93 cents, on sales of $10.1 billion, topping expectations of $9.7 billion. Sales fell 12% from a year earlier $11.5 billion. Organic sales fell 6.1%.
Fourth-quarter worldwide nutrition sales declined 11.1% due to manufacturing disruptions to baby formula production in 2022 at a plant in Sturgis, Mich., where an inspection conducted by the Food and Drug Administration found traces of Cronobacter sakazakii, a bacteria deadly to infants.
The company issued 2023 full-year adjusted guidance of $4.30 to $4.50 a share, Wall Street analysts had penciled in $4.41 a share, according to FactSet.
Write to Emily Dattilo at email@example.com